Fresenius Kabi PharmaHelp 5.1.759.0 information disclosure

CVSS Meta Temp Score
CVSS is a standardized scoring system to determine possibilities of attacks. The Temp Score considers temporal factors like disclosure, exploit and countermeasures. The unique Meta Score calculates the average score of different sources to provide a normalized scoring system.
Current Exploit Price (≈)
Our analysts are monitoring exploit markets and are in contact with vulnerability brokers. The range indicates the observed or calculated exploit price to be seen on exploit markets. A good indicator to understand the monetary effort required for and the popularity of an attack.
CTI Interest Score
Our Cyber Threat Intelligence team is monitoring different web sites, mailing lists, exploit markets and social media networks. The CTI Interest Score identifies the interest of attackers and the security community for this specific vulnerability in real-time. A high score indicates an elevated risk to be targeted for this vulnerability.
6.6$0-$5k0.00

Summaryinfo

A vulnerability marked as problematic has been reported in Fresenius Kabi PharmaHelp 5.1.759.0. Affected by this vulnerability is an unknown functionality. This manipulation causes information disclosure. This vulnerability is tracked as CVE-2022-45611. No exploit exists.

Detailsinfo

A vulnerability was found in Fresenius Kabi PharmaHelp 5.1.759.0. It has been declared as problematic. Affected by this vulnerability is an unknown code. The manipulation with an unknown input leads to a information disclosure vulnerability. The CWE definition for the vulnerability is CWE-200. The product exposes sensitive information to an actor that is not explicitly authorized to have access to that information. As an impact it is known to affect confidentiality. The summary by CVE is:

An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.

The weakness was disclosed 08/23/2023. This vulnerability is known as CVE-2022-45611 since 11/21/2022. The technical details are unknown and an exploit is not publicly available. The attack technique deployed by this issue is T1592 according to MITRE ATT&CK.

There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.

Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.

Productinfo

Vendor

Name

Version

CPE 2.3info

CPE 2.2info

CVSSv4info

VulDB Vector: 🔍
VulDB Reliability: 🔍

CVSSv3info

VulDB Meta Base Score: 6.6
VulDB Meta Temp Score: 6.6

VulDB Base Score: 3.5
VulDB Temp Score: 3.5
VulDB Vector: 🔍
VulDB Reliability: 🔍

NVD Base Score: 9.8
NVD Vector: 🔍

CVSSv2info

AVACAuCIA
💳💳💳💳💳💳
💳💳💳💳💳💳
💳💳💳💳💳💳
VectorComplexityAuthenticationConfidentialityIntegrityAvailability
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock

VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍

Exploitinginfo

Class: Information disclosure
CWE: CWE-200 / CWE-284 / CWE-266
CAPEC: 🔍
ATT&CK: 🔍

Physical: No
Local: No
Remote: Yes

Availability: 🔍
Status: Not defined

EPSS Score: 🔍
EPSS Percentile: 🔍

Price Prediction: 🔍
Current Price Estimation: 🔍

0-DayUnlockUnlockUnlockUnlock
TodayUnlockUnlockUnlockUnlock

Threat Intelligenceinfo

Interest: 🔍
Active Actors: 🔍
Active APT Groups: 🔍

Countermeasuresinfo

Recommended: no mitigation known
Status: 🔍

0-Day Time: 🔍

Timelineinfo

11/21/2022 🔍
08/23/2023 +274 days 🔍
08/23/2023 +0 days 🔍
09/16/2023 +24 days 🔍

Sourcesinfo

Advisory: fresenius-kabi.com
Status: Not defined

CVE: CVE-2022-45611 (🔍)
GCVE (CVE): GCVE-0-2022-45611
GCVE (VulDB): GCVE-100-237787

Entryinfo

Created: 08/23/2023 10:26
Updated: 09/16/2023 08:53
Changes: 08/23/2023 10:26 (36), 09/16/2023 08:52 (1), 09/16/2023 08:53 (11)
Complete: 🔍
Cache ID: 216::103

Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.

Discussion

No comments yet. Languages: en.

Please log in to comment.

◂ PreviousOverviewNext ▸

Do you need the next level of professionalism?

Upgrade your account now!